Epidemiology of RBC Transfusions in Patients With Severe Acute Kidney Injury: Analysis From the Randomized Evaluation of Normal Versus Augmented Level Study
Rinaldo Bellomo, Johan Martensson, Kirsi-Maija Kaukonen, Serigne Lo, Martin Gallagher, Alan Cass, John Myburgh, Simon Finfer
CRITICAL CARE MEDICINE | LIPPINCOTT WILLIAMS & WILKINS | Published : 2016
OBJECTIVE: To assess the epidemiology and outcomes associated with RBC transfusion in patients with severe acute kidney injury requiring continuous renal replacement therapy. DESIGN: Post hoc analysis of data from a multicenter, randomized, controlled trial. SETTING: Thirty-five ICUs in Australia and New Zealand. PATIENTS: Cohort of 1,465 patients enrolled in the Randomized Evaluation of Normal versus Augmented Level replacement therapy study. INTERVENTIONS: Daily information on morning hemoglobin level and amount of RBC transfused were prospectively collected in the Randomized Evaluation of Normal versus Augmented Level study. We analyzed the epidemiology of such transfusions and their asso..View full abstract
Awarded by National Health and Medical Research Council of Australia
Awarded by Health Research Council (HRC) of New Zealand
Supported, in part, by grants from the National Health and Medical Research Council of Australia (grant 352550) and Health Research Council (HRC) of New Zealand (grant 06-357).Dr. Bellomo received consulting fees as an advisor for Gambro and consulted for Gambro, Biosite, Abbott, and Philipps. Dr. Martensson received travel support to present research results at scientific meetings from Gambro; and received funding from Karolinska Institutet. Dr. Kaukonen received support from a grant for Clinical Research Career from the Academy of Finland. Dr. Gallagher received honoraria/speaking fees from Roche. Dr. Cass was supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship, received funding from the Australian National Health and Medical Research Council, and received grant support from Roche and Gambro. Dr. Myburgh received funding from the NHMRC (Australia) and honoraria/speaking fees and grant support from Fresenius. His institution consulted for Baxter Pharmaceuticals and received grant support from Fresenius Kabi and Baxter (received unrestricted grants and logistical support in relation to the conduct of investigator-initiated trials). Dr. Finfer has received travel support to present research results at scientific meetings from Eli Lilly, Cardinal Health, and CSL Bioplasma and received funding from the Australian National Health and Medical Research Council. The George Institute for International Health, an independent not-for-profit institute affiliated with the University of Sydney, has received reimbursement for Dr. Finfer's time as a steering committee member for studies sponsored by Eli Lilly and Eisai. The George Institute has received research funding from Servier, Novartis, Eisai, Merck, Sharp & Dohme, Pfizer Australia, Fresenius Kabi Deutschland GmbH, and Sanofi Aventis. Dr. Lo disclosed that he does not have any potential conflicts of interest.